top of page

MK677 / IBUTAMOREN

Age Management of West Michigan

Integrative Medicine

Conventional, Functional, and Anti-Aging Regenerative Medicine located in Grand Rapids, MI.
Dr. Shahnaz Ali            Dr. Piyush Bhatnagar

Peptide MK677 Ibutamoren

MK677 / IBUTAMOREN

Ibutamoren is a non-peptide growth hormone (GH) secretagogue that mimics the GH stimulating action of the hormone ghrelin.  Ibutamoren has clinically demonstrated the ability to increase endogenous release of GH as well as insulin like growth factor 1 (IGF-1) without the adverse increase of prolactin or cortisol often seen with GHRPs. 

How does MK677 increase Growth Hormone release?

Ibutamoren mimicks the action of the hormone ghrelin and binds to ghrelin receptors (GHSR) in the hypothalamus.   The activated GHSR receptors signal the anterior pituitary to increase the amplitude and frequency of growth hormone release pulses.

MK677 is utilized by patients for its ability to both increase lean muscle, bone density, and promote overall growth and recovery from exercise.

MK677 / Ibutamoren Benefits

  • Increase Lean body mass

  • Increase bone density through increasing calcium retention and mineralization of bone.

  • Accelerate healing and recovery from activity/exercise/injury.

  • Increase energy and vitality

  • Increase sexual performance and desire

  • Improved mental clarity (improved memory, decrease depression)

  • Improve sleep quality by promoting non-REM slow wave sleep

  • Enhanced immune system function

  • Improved skin health and elasticity

  • Strengthen the heart and all organ systems

  • Increase protein synthesis

  • Increase IGF-1 production

MK677 / Ibutamoren Administration

25mg oral capsule / 1 x daily

MK677 / Ibutamoren risks and side effects

  • Increase in appetite

  • Transient edema and fluid retention

  • Transient joint and muscle pain 

  • Bloating

  • Elevated fasting blood glucose

MK677 and Sermorelin:  The ultimate HGH stack

MK677 and Sermorelin can be administered in combination to stimulate natural human growth hormone production and release.   Since MK677 stimulates HGH release via ghrelin pathways and Sermorelin stimulates HGH production via GHRH (Growth Hormone Releasing Hormone) pathways they can work synergistically to optimize HGH levels.

MK677 can be used in conjunction with following treatments:

  • BHRT, TRT, Sermorelin, and HCG. 

  • Other Peptide Therapies:  BPC157 / AOD9604 KPV / TB500 / Tesofensine

doctor-patient-talking.jpg
Schedule your consultation 
Research and References

1.  Svensson J, Lönn L, Jansson JO, et al. Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure. J Clin Endocrinol Metab. 1998;83(2):362-9.

2.  Kim KR, Nam SY, Song YD, Lim SK, Lee HC, Huh KB. Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction in obese adults. Horm Res. 1999;51(2):78-84.

3.  Tavares ABW, Micmacher E, Biesek S, et al. Effects of Growth Hormone Administration on Muscle Strength in Men over 50 Years Old. International Journal of Endocrinology. 2013;2013:942030. doi:10.1155/2013/942030.

4.  Velloso CP. Regulation of muscle mass by growth hormone and IGF-I. British Journal of Pharmacology. 2008;154(3):557-568. doi:10.1038/bjp.2008.153.

5.  Johannsson G, Grimby G, Sunnerhagen KS, Bengtsson BA. Two years of growth hormone (GH) treatment increase isometric and isokinetic muscle strength in GH-deficient adults. J Clin Endocrinol Metab. 1997;82(9):2877-84.

6.  Harman SM, Blackman MR. The effects of growth hormone and sex steroid on lean body mass, fat mass, muscle strength, cardiovascular endurance and adverse events in healthy elderly women and men. Horm Res. 2003;60(Suppl 1):121-4.

7.  Murphy MG, Plunkett LM, Gertz BJ, et al. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab. 1998;83(2):320-5.

8.  Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial. Ann Intern Med. 2008;149(9):601-11.

9.  Chapman IM, Pescovitz OH, Murphy G, et al. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults. J Clin Endocrinol Metab. 1997;82(10):3455-63.

10.  Murphy MG, Bach MA, Plotkin D, et al. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group. J Bone Miner Res. 1999;14(7):1182-8.

11.  Murphy MG, Weiss S, Mcclung M, et al. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab.  2001;86(3):1116-25.  

12.  Kuzma M, Payer J. [Growth hormone deficiency, its influence on bone mineral density and risk of osteoporotic fractures]. Cas Lek Cesk. 2010;149(5):211-6.

13.  Krantz E, Trimpou P, Landin-wilhelmsen K. Effect of Growth Hormone Treatment on Fractures and Quality of Life in Postmenopausal Osteoporosis: A 10-Year Follow-Up Study. J Clin Endocrinol Metab. 2015;100(9):3251-9.

14.  Copinschi G, Leproult R, Van onderbergen A, et al. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology. 1997;66(4):278-86.

15.  Moreno-Reyes R, Kerkhofs M, L’hermite-balériaux M, Thorner MO, Van Cauter E, Copinschi G. Evidence against a role for the growth hormone-releasing peptide axis in human slow-wave sleep regulation. Am J Physiol. 1998;274(5 Pt 1): E779-84.

16.  Haqq AM, Stadler DD, Jackson RH, Rosenfeld RG, Purnell JQ, Lafranchi SH. Effects of growth hormone on pulmonary function, sleep quality, behavior, cognition, growth velocity, body composition, and resting energy expenditure in Prader-Willi syndrome. J
Clin Endocrinol Metab. 2003;88(5):2206-12.

17.  Moreno-reyes R, Kerkhofs M, L’hermite-balériaux M, Thorner MO, Van cauter E, Copinschi G. Evidence against a role for the growth hormone-releasing peptide axis in human slow-wave sleep regulation. Am J Physiol. 1998;274(5 Pt 1):E779-84.

18.  Levada OA, Troyan AS. Insulin-like growth factor-1: a possible marker for emotional and cognitive disturbances, and treatment effectiveness in major depressive disorder. Annals of General Psychiatry. 2017;16:38. doi:10.1186/s12991-017-0161-3.

19.  Copinschi G, Leproult R, Van onderbergen A, et al. Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology. 1997;66(4):278-86.

20.  van Dam PS, Aleman A. Insulin-like growth factor-I, cognition and brain aging. Eur J Pharmacol. 2004;490(1–3):87–95.

21.  Bove RM, White CC, Gerweck AV, et al. Effect of growth hormone on cognitive function in young women with abdominal obesity. Clinical endocrinology. 2016;84(4):635-637. doi:10.1111/cen.12996.

22.  Vitiello MV, Moe KE, Merriam GR, Mazzoni G, Buchner DH, Schwartz RS. Growth hormone releasing hormone improves the cognition of healthy older adults. Neurobiol Aging. 2006;27(2):318-23.

23.  Dioufa N, Schally AV, Chatzistamou I, et al. Acceleration of wound healing by growth hormone-releasing hormone and its agonists. Proc Natl Acad Sci USA. 2010;107(43):18611-5.

24.  Florea V, Majid SS, Kanashiro-takeuchi RM, et al. Agonists of growth hormone-releasing hormone stimulate self-renewal of cardiac stem cells and promote their survival. Proc Natl Acad Sci USA. 2014;111(48):17260-5.

25.  Hattori N. Expression, regulation and biological actions of growth hormone (GH) and ghrelin in the immune system. Growth Horm IGF Res. 2009;19(3):187-97.

26.  Masternak MM, Bartke A. Growth hormone, inflammation and aging. Pathobiology of Aging & Age Related Diseases. 2012;2:10.3402/pba.v2i0.17293. doi:10.3402/pba.v2i0.17293.

27.  Koo GC, Huang C, Camacho R, et al. Immune enhancing effect of a growth hormone secretagogue. J Immunol. 2001;166(6):4195-201.

28.  Smith TJ. Insulin-Like Growth Factor-I Regulation of Immune Function: A Potential Therapeutic Target in Autoimmune Diseases? Pharmacological Reviews. 2010;62(2):199-236. doi:10.1124/pr.109.002469.

29.  Bilbao D, Luciani L, Johannesson B, Piszczek A, Rosenthal N. Insulin-like growth factor-1 stimulates regulatory T cells and suppresses autoimmune disease. EMBO Molecular Medicine. 2014;6(11):1423-1435. doi:10.15252/emmm.201303376.

30.  Brod M, Pohlman B, Højbjerre L, Adalsteinsson JE, Rasmussen MH. Impact of adult growth hormone deficiency on daily functioning and well-being. BMC Research Notes. 2014;7:813. doi:10.1186/1756-0500-7-813.

bottom of page